On July 8, 2024, San Francisco, USA and Suzhou, China / PRNewswire/ - Environmental, social and governance (ESG) are key indicators for assessing a company's long-term sustainable development. Innovent Bio has always actively responded to the United Nations Sustainable Development Goals (SDGs) and assisted in the implementation of the Health China strategy. Green and sustainable development is a long-term important development strategy for the company. Recently, Innovent bio-pharmaceutical group officially launched the environmental, social and governance (ESG) official website, marking the company's firm practice commitment to sustainability, corporate responsibility, and ethical business behavior, while highlighting the company's comprehensive progress and outstanding achievements in excellent governance, benefiting health, quality first, people-oriented, and green ecology. Innovent Bio is taking concrete actions to lead the pharmaceutical industry towards a greener and more responsible future.
The newly launched ESG website is a comprehensive platform that displays the company's measures, policies, and performance in key areas of ESG focus, including:
Excellent governance
Innovent Bio has a transparent corporate governance structure, high standards of ethical business practices, lean and efficient business operations, and sound risk management and consciously strictly comply with regulations, which constitute the basis of Innovent Bio's business behavior. The company bases its business on integrity, believes that good corporate governance and all-round efficient management can help companies develop steadily, have the ability to precipitate across cycles, and create sustainable value for society.
Benefiting Health
Innovent bio-pharmaceutical is dedicated to innovative drug development, focusing on building a strong product portfolio in the fields of tumors and comprehensive products, and expanding its global innovation product line to 36. Innovent Bio has launched 10 innovative products, of which 5 are included in the national medical insurance directory, benefiting more than 2.5 million patients. Innovent Bio has always adhered to the scientific concept of "life first", continuously self-researched and innovated drugs, and sought its own development, upheld the development thought of economic construction centering on the people, adhered to the principle of "patient-centered", cared about patients and their families, and implemented universal medical care through a series of patient assistance programs to improve drug accessibility and affordability, actively fulfilling social responsibilities and creating broader health value.
Quality First
Innovent bio-pharmaceutical has always put the quality and safety of drugs first, has established a comprehensive quality control system that complies with Chinese and international standards, and has invested in operating capacity of up to 0.14 million liters to ensure that our products meet high-quality standards throughout their lifecycle. We extend our pursuit of high quality to all aspects of production process optimization, operation efficiency improvement, and building a sustainable supply chain. Meanwhile, in marketing work, Innovent Bio continuously deepens the service, practices responsible marketing, protects the rights and privacy of patients responsibly.
People-oriented
Innovent bio-pharmaceutical is committed to creating a safe, diverse, fair, inclusive and respectful working environment, and providing employees with diverse promotion and professional development opportunities, and implementing a sound salary and welfare system and employee care measures, constantly improving employees' sense of belonging, promoting talent attraction, retention and development. In 2023, Innovent Bio's female employees accounted for more than 50% and employee satisfaction exceeded 98%.
Green Ecology
Innovent Bio has taken active measures to promote green development, including continuously optimizing the environmental management system, and practicing environmental and resource protection in the company's daily business management and product lifecycle activities. Currently, all of the company's operating production bases have obtained the ISO 14001 environmental management system certification. In 2023, the company further deepened its exploration and practice of environmental management, improved environmental management performance through effective measures, set clear environmental management goals, and formulated strategies and guarantee systems to actively respond to climate change.
In 2023, based on its outstanding performance in the ESG field, Innovent Bio received an "A" ESG rating from the international authoritative rating agency Morgan Stanley Capital International (MSCI), leading the China pharmaceutical industry. Through the ESG website, stakeholders including investors, partners, employees, consumers and community members can obtain detailed information on Innovent Bio's ESG performance, goals and progress reports.
Dr. Dechao Yu, the founder, chairman and CEO of Innovent Bio-pharmaceutical"Innovent bio has always been committed to integrating environmental, social, and governance (ESG) principles into its business operations. Our newly launched ESG website not only reflects our adherence to transparency, accountability, and sustainability principles, but also demonstrates our positive actions in the following areas: ensuring transparent and accountable governance, building a strong product portfolio covering both tumor and comprehensive areas, ensuring high-quality standards in the entire supply chain, caring for employee welfare, and adopting environmentally friendly and sustainable business models. We believe that by prioritizing these ESG key areas in our strategic positioning, we can create lasting value for all stakeholders and make a positive contribution to promoting a more sustainable future."
To learn more about Innovent Bio's ESG initiatives and explore the new ESG website, please visit .
"Starting with trust and ending with action", developing high-quality biopharmaceuticals that the general public can afford is the ideal and goal of Innovent Biologics. Innovent Biologics was established in 2011 and is committed to the development, production, and sales of innovative drugs to treat major diseases such as tumors, metabolic diseases, and autoimmune diseases. On October 31, 2018, Innovent Biologics went public on the Main Board of the Hong Kong Stock Exchange with stock code: 01801. Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model. It has established a product chain including 23 new drug varieties, covering multiple disease areas such as tumors, metabolic diseases, and autoimmune diseases, of which 6 varieties have been selected for the national "Major New Drug Creation" special project, and 3 products (Sintilimab Injection, brand name: Tyvyt, English trademark: TYVYT; Bevacizumab Injection, brand name: Duligotong, English trademark: BYVASDA; Camrelizumab Injection, brand name: Sulinno, English trademark: SULINNO) have been approved.
"Starting from trust, achieving through actions", developing high-quality bio-pharmaceuticals that the lbx pharmacy chain joint stock can afford is Innovent Bio's mission and goal. Innovent Bio was established in 2011 and is committed to researching, developing, producing, and selling innovative drugs in major disease fields such as tumors, autoimmunity, metabolism, ophthalmology, and more to benefit more lives. The company has obtained approval for 10 products, namely sintilimab injection (Tyvyt), bevacizumab injection (Avastin), adalimumab injection (Humira), rituximab injection (Rituxan)"Starting from trust, achieving through actions", developing high-quality bio-pharmaceuticals that the lbx pharmacy chain joint stock can afford is Innovent Bio's mission and goal. Innovent Bio was established in 2011 and is committed to researching, developing, producing, and selling innovative drugs in major disease fields such as tumors, autoimmunity, metabolism, ophthalmology, and more to benefit more lives. The company has obtained approval for 10 products, namely sintilimab injection (Tyvyt), bevacizumab injection (Avastin), adalimumab injection (Humira), rituximab injection (Rituxan)"Starting from trust, achieving through actions", developing high-quality bio-pharmaceuticals that the lbx pharmacy chain joint stock can afford is Innovent Bio's mission and goal. Innovent Bio was established in 2011 and is committed to researching, developing, producing, and selling innovative drugs in major disease fields such as tumors, autoimmunity, metabolism, ophthalmology, and more to benefit more lives. The company has obtained approval for 10 products, namely sintilimab injection (Tyvyt), bevacizumab injection (Avastin), adalimumab injection (Humira), rituximab injection (Rituxan)"Starting from trust, achieving through actions", developing high-quality bio-pharmaceuticals that the lbx pharmacy chain joint stock can afford is Innovent Bio's mission and goal. Innovent Bio was established in 2011 and is committed to researching, developing, producing, and selling innovative drugs in major disease fields such as tumors, autoimmunity, metabolism, ophthalmology, and more to benefit more lives. The company has obtained approval for 10 products, namely sintilimab injection (Tyvyt), bevacizumab injection (Avastin), adalimumab injection (Humira), rituximab injection (Rituxan)Pemtinib tablets (Dabotan), Alectinib tablets (Nairitak), Ramucirumab injection (Xiranze), Sepitinib capsules (Ruituo), Ikuolunsai injection (Fukesu) and Toriexi monoclonal antibody injection (Xinbile). At present, there are also 4 varieties in NMPA evaluation, 4 new drug molecules entering phase III or key clinical studies, and another 18 new drug varieties have entered clinical research. The company has reached more than 30 strategic cooperation agreements with international partners such as Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center. While seeking self-development through independent research and development of innovative drugs, Innovent adheres to the development concept of economic construction centering on the people. Over the years, it has always had a scientific and kind heart, stuck to the principle of "patient-centered," concerned about the patients and their families, and actively fulfilled its social responsibilities. The company has launched and participated in a number of drug public welfare assistance projects, enabling more and more patients to benefit from the progress of life sciences and buy and afford high-quality biological drugs. Up to now, Innovent's patient assistance project has benefited more than 170,000 ordinary patients, and the total value of drug donations is 3.4 billion yuan. Innovent hopes to work together with everyone to improve the development level of China's biopharmaceutical industry, to meet the accessibility of the people's medication and the pursuit of a better life and health.Ramucirumab injection (Xiranze) and Sepitinib capsules (Ruituo) are developed by Eli Lilly. Declaration: Innovent does not recommend the use of unapproved drugs/indications. Sepcitinib capsules (Ruituo)Mazdutide (IBI362) is a GLP-1R/GCGR dual agonist jointly developed by Innovent Bio and Eli Lilly and Co. As a somatostatin analogue similar to human gastric inhibitory polypeptide (OXM), Mazdutide not only promotes insulin secretion, lowers blood sugar, and reduces weight by stimulating GLP-1R, but also increases energy consumption and enhances weight loss by stimulating GCGR, while improving liver fat metabolism. Mazdutide has shown excellent weight loss and hypoglycemic effects, as well as multiple metabolic benefits in reducing waist circumference, blood lipids, blood pressure, uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity, in multiple clinical studies. Currently, five Phase III clinical studies of Mazdutide are underway in Chinese overweight or obese participants (GLORY-1 and GLORY-2) and type 2 diabetes participants (DREAMS-1, DREAMS-2, and DREAMS-3). Among them, the GLORY-1 and DREAMS-2 studies have achieved their primary endpoints.*Phocoena (Icotinib)Tollezumab injection (Xinbile)Currently, there are also 4 varieties under NMPA review, 4 new drug molecules entering Phase III or pivotal clinical trials, and an additional 18 new drug varieties entering clinical trials.
Innovent Biologics has reached more than 30 strategic cooperation agreements with international partners such as Eli Lilly and Co, Roche, Sanofi, Adimab, Incyte, and MD Anderson Cancer Center. While constantly innovating and researching and developing new drugs, Innovent adheres to the concept of people-centered economic development. Over the years, Innovent has always aimed to fulfill the social responsibility of science and technology while advocating the idea of "patient-centered," caring about patients and their families, and actively fulfilling social responsibility. The company has launched and participated in multiple drug public welfare assistance projects, enabling more and more patients to benefit from the progress of life science and to buy and afford high-quality biological drugs. By the end of 2023, Innovent Biologics' patient assistance projects had benefited more than 170,000 ordinary patients, with a total drug donation value of 3.4 billion RMB. Innovent Biologics hopes to work together with everyone to improve the development level of China's biopharmaceutical industry and to meet the people's demand for accessible and affordable medicine and their pursuit of good health and well-being.
Statement: Innovent Bio does not recommend unapproved drugs.
*Removab injection solution (cimazaxomab) and Septinib capsules (Retevmo) were developed by Eli Lilly and Co.Innovent Bio's RuoTai capsules and Septrini capsulesDeveloped by Eli Lilly and Co.
Forward-looking statements
This press release may contain certain forward-looking statements. These statements inherently involve risks and uncertainties. When using words such as "expect," "believe," "anticipate," "intend," "plan," and other similar expressions, it is the company's intention to identify forward-looking statements. The company has no obligation to continually update these forward-looking statements.
These forward-looking statements are based on management's current views, assumptions, expectations, estimates, forecasts, and understandings of future events, which are inherently subject to risks, uncertainties, and other factors, some of which are beyond the company's control, and may be difficult to predict. Therefore, actual results may differ materially from those included in the forward-looking statements due to future changes and developments in our business, competitive environment, politics, economy, laws, and social circumstances.